Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0313 • ACR Convergence 2020
Swollen Joints but Not Tender Joints Are Associated with Ultrasound Power Doppler Synovitis in Very Early DMARD Naive Psoriatic Arthritis
Sayam Dubash¹, Oras Alabas¹, Xabier Michelena¹, Leticia Garcia-Montoya¹, Gabriele De Marco², Mira Merashli³, Richard Wakefield¹, Philip Helliwell⁴, Ai Lyn Tan¹, Dennis McGonagle¹, Paul Emery⁵ and Helena Marzo-Ortega¹, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Treviglio, Italy, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Beirut, Lebanon, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Clinical tender and swollen joint counts are used for biologic drug eligibility and clinical trial inclusion criteria. Ultrasonography (US) adds to clinical examination as…
Abstract Number: 0329 • ACR Convergence 2020
Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis
Alexis Ogdie¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Steven Sison³, Jason Shafrin³, Sofia Pedro⁴, Peter Hur⁵, Nina Kim⁶ and Kaleb Michaud⁷, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, ⁴FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶The University of Texas at Austin; Baylor Scott and White Health, Austin, TX, ⁷FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita
Background/Purpose: The Health Assessment Questionnaire Disability Index (HAQ-DI) has been validated and widely used in psoriatic arthritis (PsA) clinical trials for the assessment of patient…
Abstract Number: 0347 • ACR Convergence 2020
In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
Proton Rahman¹, Philip Helliwell², Atul Deodhar³, Alexa Kollmeier⁴, Elizabeth Hsia⁵, Bei Zhou⁶, Xiwu Lin⁶, Chenglong Han⁶ and Philip Mease⁷, ¹Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Janssen Research & Development, LLC, La Jolla, CA, ⁵Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2 are phase-3 trials of guselkumab (GUS, an IL-23 inhibitor) in patients with psoriatic arthritis (PsA). In both trials, treatment with…
Abstract Number: 0375 • ACR Convergence 2020
Efficacy of Disease Modifying Anti-Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort
Ashish Mathew¹, Mitchell Sutton², Daniel Pereira², Vinod Chandran³ and Dafna Gladman³, ¹University Health Network, Vellore, Tamil Nadu, India, ²Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is a common clinical feature of psoriatic arthritis (PsA). There is limited evidence on the effect of treatment on enthesitis. Our purpose was…
Abstract Number: 0546 • ACR Convergence 2020
Stepping up for Inflammatory Arthritis (SUFIA): A Pilot Trial to Test Behavioral Economics Strategy to Increase Physical Activity in Inflammatory Arthritis
Alexis Ogdie¹, Kathleen Bush¹, Michael George¹, Mitesh Patel¹, William Nowell², Kelly Gavigan³, Jeffrey Curtis⁴ and Joshua Baker⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, New York City, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Regular physical activity may have benefits for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but patients with active disease are often reluctant…
Abstract Number: 0901 • ACR Convergence 2020
Proinflammatory Neutrophil Function Is Modulated During Secukinumab Therapy in Psoriatic Arthritis Without Compromising Host Defence
Robert Moots¹, Andy Cross², Helen Wright², Steven Edwards², Nicola Goodson³, Jenny Hawkes³, Ayren Mediana¹ and Helen Frankland¹, ¹Liverpool University Hospitals, Liverpool, United Kingdom, ²University of Liverpool, Liverpool, United Kingdom, ³University of Liverpool, Liverpool
Background/Purpose: Secukinumab is a monoclonal antibody that neutralises IL-17A, which plays a key role in the IL-23/17A axis underlying the pathophysiology of psoriatic arthritis (PsA). …
Abstract Number: 1314 • ACR Convergence 2020
Fatigue in Psoriatic Arthritis (PsA): Prevalence in Patients from the US and Europe, and Impact on Quality of Life and Work Productivity
Jessica Walsh¹, Kaleb Michaud², Elizabeth Holdsworth³, Steven Peterson⁴, Nicola Booth³, Sophie Meakin³, Soumya Chakravarty⁵, James Piercy³ and Alexis Ogdie⁶, ¹University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ²University of Nebraska Medical Center, Omaha, NE, ³Adelphi Real World, Bollington, United Kingdom, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁶Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Fatigue is an important aspect of PsA for patients. Understanding the impact of fatigue on patient reported outcomes is important for effective management of…
Abstract Number: 1351 • ACR Convergence 2020
Efficacy of Ixekizumab versus Adalimumab in Psoriatic Arthritis (PsA) Patients with and Without Moderate-to-severe Psoriasis: 52-week Results from a Multicentre, Randomised Open-label Study
Lars Erik Kristensen¹, Masato Okada², William Tillett³, Soyi Liu-Leage⁴, Celine El Baou⁵, Andrew Bradley⁵, Gabriella Meszaros⁴ and Kurt de Vlam⁶, ¹The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ²St. Luke's International University, Tokyo, Japan, Chuo-ku, Tokyo, Japan, ³Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁶Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium
Background/Purpose: Ixekizumab (IXE), a selective interleukin-17A antagonist, is approved for the treatment of active PsA, moderate-to-severe psoriasis (PsO), and radiographic/non-radiographic axial SpA in adults. The…
Abstract Number: 1520 • ACR Convergence 2020
Characterisation of Rheumatoid and Psoriatic Arthritis Synovial Fibroblasts
Clare Cunningham¹, Sharon Ansboro¹, Sarah Wade¹, Candice Low², Ronan Mullan³, Douglas Veale⁴ and Ursula Fearon⁵, ¹Trinity College Dublin, Dublin, Ireland, ²EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, ³Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁴EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, ⁵Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland
Background/Purpose: The synovial inflammation observed in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) is characterised by synovial fibroblast hyperplasia, leukocyte infiltration, neoangiogenesis and hypoxia. These…
Abstract Number: 1981 • ACR Convergence 2020
Patients with Inflammatory Arthritis Who Are More Adherent to Treatment Do Not Perform More Physical Activity Collected by Smartphone Apps: A Cross-sectional Study of 101 Patients, the ImBAIA Study
Thomas Davergne¹, Rawdha Tekaya², Camille Deprouw³, Anne Tournadre⁴, Stéphane Mitrovic⁵, Adeline Ruyssen-Witrand⁶, Christophe Hudry⁷, Sabrina Dadoun⁸, Jérôme Avouac⁹, Kate Betteridge¹⁰, Bruno Fautrel¹¹ and Laure Gossec¹², ¹Sorbonne University, INSERM, IPLES, Paris, France, ²Hôpital Charles Nicolle, Rheumatology department, Tunis, Tunisia, Tunis, Tunisia, ³1. AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Paris, 75012, France, Paris, France, ⁴CHU Gabriel Montpied, Clermont-Ferrand, ⁵Institut Mutualiste Montsouris, Rheumatology department, Paris, France, Paris, Ile-de-France, France, ⁶Hôpital Purpan, CHU Toulouse, Toulouse, France, ⁷CeSOA, MGEN, Paris, France, Paris, Ile-de-France, France, ⁸Medical centre, Paris, France, paris, Ile-de-France, France, ⁹Cochin hospital, Rheumatology department, Paris, France, Paris, Ile-de-France, France, ¹⁰Patient research partner, UK, london, England, United Kingdom, ¹¹Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹²Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Adherence to both medications and physical activity is insufficient in patients with inflammatory arthritis (IA), such as spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic…
Abstract Number: 0155 • ACR Convergence 2020
Changes in Patient-Reported Outcome (PRO) Scores for Nausea and Fatigue Following Weekly Methotrexate Dose in a Real-World Sample of RA and PsA Patients in the ArthritisPower Registry
William Nowell¹, Elaine Karis², Kelly Gavigan³, Laura Stradford³, Scott Stryker², Huifeng Yun⁴, Shilpa Venkatachalam⁵, Gregory Kricorian², Lang Chen⁴, Hong Zhao⁶, Fenglong Xie⁶ and Jeffrey R Curtis⁴, ¹Global Healthy Living Foundation, New York City, NY, ²Amgen Inc., Thousand Oaks, CA, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Global Healthy Living Foundation, Upper Nyack, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is frequently used in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) because of its beneficial effects in both populations. Despite…
Abstract Number: 0314 • ACR Convergence 2020
Accuracy of Physical Examination to Detect Synovial and Extra-synovial Pathologies in Psoriatic Arthritis in Comparison to Ultrasonography
Ummugulsum Gazel¹, Dilek Solmaz², Gizem Ayan³, Catherine Ivory⁴, Jacob Karsh⁴ and Sibel Aydin⁵, ¹University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, ottawa, Canada, ²Izmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, TURKEY, Izmir, Turkey, ³University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA, Ottawa Hospital Research Institute, OTTAWA, ON, Canada, ⁴University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA, Ottawa, ON, Canada, ⁵University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada
Background/Purpose: The aim of this study to explore the comparison of physical examination (PE) and ultrasound (US) detected synovial and extra-synovial pathologies of the hands…
Abstract Number: 0330 • ACR Convergence 2020
Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors
Timothy Kwok¹, Mitchell Sutton², Daniel Pereira², Vinod Chandran³ and Dafna Gladman³, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Despite optimal medical therapy, joint space disease and skeletal damage persists in a subset of patients with PsA, many of whom requiring musculoskeletal (MSK)…
Abstract Number: 0349 • ACR Convergence 2020
Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year
Christopher Ritchlin¹, Proton Rahman², Philip Helliwell³, Wolf-Henning Boehncke⁴, Iain McInnes⁵, Alice Gottlieb⁶, Shelly Kafka⁷, Alexa Kollmeier⁸, Elizabeth Hsia⁹, Xie Xu¹⁰, May Shawi¹¹, Shihong Sheng¹², Prasheen Agarwal¹², Bei Zhou¹², Paraneedharan Ramachandran¹³ and Philip Mease¹⁴, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Geneva University Hospitals, Geneva, Switzerland, ⁵Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ¹⁰Janssen Research & Development, LLC, San Marcos, CA, ¹¹Janssen Global Services, LLC, Toronto, ON, Canada, ¹²Janssen Research & Development, LLC, Spring House, PA, ¹³Janssen Research & Development, LLC, Horsham, ¹⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2, two double-blind, phase 3, psoriatic arthritis (PsA) trials of guselkumab (GUS, an IL-23 inhibitor), demonstrated significant improvement with GUS vs…
Abstract Number: 0377 • ACR Convergence 2020
Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Lihi Eder¹, Dafna Gladman², Sibel Zehra Aydin³, Alexis Ogdie⁴, Harry Shi⁵, Pierre-Alexandre Landry⁶ and Rayana Luna⁶, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada, ⁴Division of Rheumatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Canada ULC, Kirkland, Canada
Background/Purpose: Studies indicate that sex (male vs female) is predictive of outcomes with PsA treatments, such as TNF inhibitors (TNFi).1 Tofacitinib is an oral JAK…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].